Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Geyer

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
Histopathology|December 3, 2017
Invasion in breast lesions: the role of the epithelial-stroma barrierEmad A Rakha, Islam M Miligy, Kylie L Gorringe, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
The Journal of Pathology|February 3, 2016
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progressionSalvatore Piscuoglio, Charlotte Ky Ng, Melissa Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarityFresia Pareja, Edaise M da Silva, Denise Frosina, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Nature Genetics|June 3, 2020
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapyAlejandro Jiménez-Sánchez, Paulina Cybulska, Katherine LaVigne Mager, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Nature Communications|May 10, 2018
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomasFelipe C Geyer, Anqi Li, Anastasios D Papanastasiou, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
Histopathology|December 3, 2017
Invasion in breast lesions: the role of the epithelial-stroma barrierEmad A Rakha, Islam M Miligy, Kylie L Gorringe, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
The Journal of Pathology|February 3, 2016
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progressionSalvatore Piscuoglio, Charlotte Ky Ng, Melissa Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarityFresia Pareja, Edaise M da Silva, Denise Frosina, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Nature Genetics|June 3, 2020
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapyAlejandro Jiménez-Sánchez, Paulina Cybulska, Katherine LaVigne Mager, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Nature Communications|May 10, 2018
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomasFelipe C Geyer, Anqi Li, Anastasios D Papanastasiou, et al.
Pageof 18